For immediate release
Radiant Genomics, Inc. Awarded an SBIR Phase I Grant
Emeryville, CA, August 31, 2013 – Radiant Genomics, Inc. is pleased to announce it has been awarded a Phase I Small Business Industrial Research (SBIR) grant from the National Institute of General Medical Sciences, part of the National Institutes of Health, for the project titled “A Synthetic Biology Toolbox for Natural Product Discovery from Actinomycetes.”
“This is an important milestone as we build out technology for our next-generation natural products discovery platform,” said Dr. Jeffrey Kim, CSO of Radiant Genomics, Inc. “We are extremely excited that our technology and vision for the future of the natural products field was so well received by the reviewers on this SBIR panel. We look forward to using this grant money to achieve the aims set out in our proposal”.
About the Company
Radiant Genomics, Inc. was founded in 2012 with the goal of integrating a range of novel technologies including large-scale sequencing, synthetic biology, bioinformatics, cloud computing, metabolic engineering, and high-throughput analytical chemistry to develop a robust industrial platform for natural product discovery, diversification, and production. Radiant Genomics utilizes this platform to develop products in numerous market categories including pharmaceuticals, agriculture, specialty chemicals, and nutraceuticals.